drugset / Trial / NCT02860715

Clinical Trial of GX-I7 in Healthy Volunteers

NCT02860715

Phase 1 Completed 30 enrolled Genexine, Inc.
RandomizedParallel-groupQuadruple-blindScreening

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GX-I7 in healthy volunteers.

Timeline

Start
2016-07-11
Primary completion
2017-01-20
Completion
2018-06-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject NT-I7 Protein / enzyme biologic 20 ug/kg Subcutaneous
Subject NT-I7 Protein / enzyme biologic 60 ug/kg Subcutaneous

Indications

No indication recorded.